Order Summary

In order to access content on the Celltelligence Library, you must have an account.

The price for access is $0.00.

Do you have a discount code? Click here to enter your discount code.

Account Information Already have an account? Log in here


By selecting this, I agree to receive emails from celltelligence.com.

You will be granted access to your Celltelligence Library to view the full article after sign up.

Type II Variations for Yescarta and Breyanzi Listed in September’s CHMP Agenda

Here is a brief preview of this blast: On Monday, September 12, the CHMP agenda for September was released. Of note, Yescarta (Gilead / Kite's CD19 CAR-T) and Breyanzi (BMS's CD19 CAR-T) have been listed under the ‘Type II Variations – Opinion or Requests for Supplementary Information’ section for r/r DLBCL and high-grade B-cell lymphoma (HGBL), and 2L DLBCL Transplant Intended (TI) patients, respectively.

About The Author

The Celltelligence Team

Content Leads & Contributors
The Celltelligence team has combined experience in oncology, including cell therapy, CAR-T, immunology, microbiology, biochemistry, and other various fields in life sciences. Our team members include PhDs, industry veterans, and analysts tuned to The Street – all of whom help to create a more actionable service of delivering cell therapy intelligence.